Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angiolix
- Development stage
- Discontinued
- Lead developer
- Access Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Angiolix is a humanized monoclonal antibody (huMc-3) designed to target lactadherin, also known as Milk fat globule-EGF factor 8 protein (MFGE8). Lactadherin is a glycoprotein that promotes tumor growth by stimulating angiogenesis, the process of new blood vessel formation. By binding to lactadherin and blocking its interaction with integrins (such as alpha-v beta-3 and alpha-v beta-5) on endothelial cells, Angiolix inhibits the development of the tumor's vascular supply and induces programmed cell death (apoptosis) in existing tumor-supporting blood vessels. Originally developed by Somanta Pharmaceuticals, the drug was acquired by Access Pharmaceuticals in 2008. It was primarily investigated as a targeted antineoplastic therapy for various types of cancer and solid tumors.
- Brand names
- Angiolix
- Other names
- huMc-3 monoclonal antibodyhuMc3 monoclonal antibodyhuMc 3 monoclonal antibodyanti-lactadherin antibody
Beyond the preview
Go deeper on Angiolix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiolix.